Rapid Decrease in Pruritus With Ruxolitinib Cream for Patients With Atopic Dermatitis: Pooled Results From TRuE-AD1 and TRuE-AD2

AAAAI February 26 - March 1, 2021, AAD VMX April 23-25, 2021; Virtual
Rapid, clinically meaningful, and continual improvement in itch observed with ruxolitinib cream for patients with atopic dermatitis.
Format: Microsoft PowerPoint (.ppt)
File Size: 453 KB
Released: June 18, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Incyte Corporation

Related Content

From Clinical Care Options (CCO) and Dr. Robert Sidbury, expert commentary on new data in atopic dermatitis evaluation and management.

Robert Sidbury, MD, MPH Released: June 30, 2021

Assessment of depth, rapidity of response of abrocitinib and dupilumab in patients with moderate to severe AD in JADE COMPARE using stringent endpoints: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Released: June 15, 2021

Characterization of skin pain in children with atopic dermatitis: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Released: June 11, 2021

Analysis of efficacy of oral azoles as a potential treatment for dupilumab facial redness: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Released: June 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue